Related references
Note: Only part of the references are listed.Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice
R. Lanzillo et al.
NEUROLOGICAL SCIENCES (2013)
Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort
Ulf Kallweit et al.
CLINICAL NEUROPHARMACOLOGY (2012)
Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
O. Fernandez et al.
JOURNAL OF NEUROLOGY (2012)
Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI(R) Observational Program (TOP) (P04.134)
L. Kappos et al.
NEUROLOGY (2012)
The Toronto Observational Study of Natalizumab in Multiple Sclerosis
Kristen M. Krysko et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2011)
Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis
S. Belachew et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Carolina Holmen et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis
J. Theodore Phillips et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome
L. Prosperini et al.
NEUROLOGICAL SCIENCES (2011)
Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study
F. Sangalli et al.
NEUROLOGICAL SCIENCES (2011)
Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries
N. Putzki et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland
Norman Putzki et al.
EUROPEAN NEUROLOGY (2010)
Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice
Olivier Outteryck et al.
JOURNAL OF NEUROLOGY (2010)
A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Shifting the Paradigm Toward Earlier Treatment of Multiple Sclerosis With Interferon Beta
Giancarlo Comi
CLINICAL THERAPEUTICS (2009)
Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study
A. B. Oturai et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
Michael Hutchinson et al.
JOURNAL OF NEUROLOGY (2009)
Maximising therapeutic outcomes in patients failing on current therapy
Christina Caon
JOURNAL OF THE NEUROLOGICAL SCIENCES (2009)
Rationale for early intervention with immunomodulatory treatments
Mar Tintore
JOURNAL OF NEUROLOGY (2008)
Oral fingolimod (FTY720) for relapsing multiple sclerosis
Ludwig Kappos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
CH Polman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A controlled trial of natalizumab for relapsing multiple sclerosis.
DH Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response
PK Coyle et al.
MULTIPLE SCLEROSIS (2002)
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis
G Comi et al.
ANNALS OF NEUROLOGY (2001)
Share Paper
